STAGE IIIB LUNG NON-SMALL CELL CANCER AJCC V7
Clinical trials for STAGE IIIB LUNG NON-SMALL CELL CANCER AJCC V7 explained in plain language.
Never miss a new study
Get alerted when new STAGE IIIB LUNG NON-SMALL CELL CANCER AJCC V7 trials appear
Sign up with your email to follow new studies for STAGE IIIB LUNG NON-SMALL CELL CANCER AJCC V7, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Could a new drug combo shrink tough lung tumors?
Disease control OngoingThis study tests whether adding the drug veliparib to standard chemotherapy and radiation helps people with stage III lung cancer that can't be removed by surgery. About 53 adults took part to find the best dose and see if the combination slows cancer growth. The goal is to impro…
Matched conditions: STAGE IIIB LUNG NON-SMALL CELL CANCER AJCC V7
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug combo shows promise in Hard-to-Treat cancers
Disease control OngoingThis study tests a combination of two drugs, cediranib and olaparib, in people with advanced solid tumors that have spread or cannot be removed by surgery. The cancers include certain types of breast, lung, and pancreatic cancer. The goal is to see if the combination can shrink t…
Matched conditions: STAGE IIIB LUNG NON-SMALL CELL CANCER AJCC V7
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Experimental drug combo aims to outsmart resistant lung cancer
Disease control OngoingThis early-phase trial tests a combination of two targeted drugs, sapanisertib and osimertinib, in people with advanced EGFR-mutant non-small cell lung cancer that has stopped responding to osimertinib alone. The main goals are to find the safest dose and understand side effects.…
Matched conditions: STAGE IIIB LUNG NON-SMALL CELL CANCER AJCC V7
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New cocktail for tough lung cancer shows promise in small trial
Disease control OngoingThis phase 2 pilot trial tested adding the drug bevacizumab to standard chemotherapy and radiation for patients with stage III non-small cell lung cancer that cannot be removed by surgery. The study enrolled 29 newly diagnosed patients to see if the combination is safe and helps …
Matched conditions: STAGE IIIB LUNG NON-SMALL CELL CANCER AJCC V7
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
Drug combo aims to outsmart resistant lung cancer
Disease control OngoingThis early-phase trial tests the combination of two oral drugs, ceritinib and everolimus, in people with advanced solid tumors or a specific type of lung cancer (ALK-positive NSCLC) that has stopped responding to standard treatments. The main goal is to find a safe dose and look …
Matched conditions: STAGE IIIB LUNG NON-SMALL CELL CANCER AJCC V7
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
Lung cancer radiation gets a precision boost: trial aims to hit tumors harder, spare healthy tissue
Disease control OngoingThis study tests whether giving a higher radiation dose directly to the tumor, while keeping the standard dose to surrounding healthy tissue, can improve outcomes for people with stage II to IIIB non-small cell lung cancer. About 146 participants will receive either photon (IMRT)…
Matched conditions: STAGE IIIB LUNG NON-SMALL CELL CANCER AJCC V7
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC